Target intelligence / Profile preview

Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE)

Target
IKBKE
Molecular classification
Enzyme, Kinase, Serine/threonine-protein kinase
01

Overview

Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE), also known as IKK-epsilon or IKK-i, is a noncanonical serine/threonine kinase belonging to the IkappaB kinase family. It plays a pivotal role in regulating both innate immune responses and oncogenic signaling pathways. Upon activation by viral infection or inflammatory cytokines, IKBKE phosphorylates key transcription factors, such as interferon regulatory factors 3 and 7 (IRF3/7) and NF-kappa-B subunits, to drive the expression of type I interferons and pro-inflammatory cytokines. In oncology, IKBKE acts as an oncogene that is frequently amplified or overexpressed in various malignancies, including breast, ovarian, pancreatic, and lung cancers, where it promotes cell survival, proliferation, metastasis, and chemoresistance. Consequently, IKBKE has emerged as an attractive therapeutic target. Small-molecule inhibitors, such as amlexanox and momelotinib, are being investigated for their ability to block IKBKE activity, thereby suppressing tumor growth and restoring sensitivity to therapies, as well as treating metabolic and autoimmune disorders.

Other names
I-kappa-B kinase epsilonIkappaB kinase epsilonIKK-epsilonIKK-EIKK-iIKKEIKKIInducible I kappa-B kinaseInhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilonNF-kappa-B-activating kinaseNAK
02

Mechanism of action

Inhibition of the kinase activity of IKBKE, preventing the phosphorylation of downstream substrates such as IRF3, IRF7, and IkappaB-alpha, thereby blocking NF-kappa-B activation and type I interferon signaling.

03

Biological functions

Signal transductionImmune responseApoptosisCell proliferationCell survivalAutophagyInflammation
04

Disease associations

CancerInflammationAutoimmune diseaseObesityType 2 diabetesInfection
05

Safety considerations

Immunosuppression and increased susceptibility to viral infectionsPotential systemic toxicity due to overlapping roles with TBK1Off-target kinase inhibition leading to adverse effects
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

IKBKE overexpressionIKBKE gene amplificationPhosphorylated YB-1 (p-YB-1)MYC expression levelsInterferon-stimulated gene (ISG) expression signatureEGFR mutation status

Beyond the preview

Go deeper on Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call